On Aug. 9, the U.S. Food and Drug Administration (FDA) approved Marqibo (vincristine sulfate liposome injection) to treat adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). Read more.
FDA approves Marqibo for rare type of leukemia
Author(s):
Most Recent Content
For Nurse Practitioners
Will Omicron Be More Contagious Than Delta?
If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...
